Related Experiment Video

Updated: Jun 17, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling

Peng Hou1, Ermal Bojdani, Mingzhao Xing

  • 1Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA.

The Journal of Clinical Endocrinology and Metabolism
|December 17, 2009
PubMed
Abstract

Insights

Targeting key signaling pathways and histone deacetylase with specific inhibitors can restore radioiodine avidity in thyroid cancer cells. This approach enhances iodide-handling gene expression and radioiodide uptake, offering potential for improved ablation therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Radioiodine ablation is a standard thyroid cancer treatment.
  • Loss of radioiodine avidity due to silenced iodide-handling genes is a major therapeutic challenge.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting MAPK, PI3K/Akt/mTOR pathways, and histone deacetylase.
  • To restore radioiodine avidity in thyroid cancer cells.

Main Methods:

  • Utilized specific inhibitors: RDEA119 (MAPK kinase), temsirolimus (mTOR), perifosine (Akt), and SAHA (histone deacetylase).
  • Tested inhibitors individually and in combination on thyroid cancer cell lines.
  • Assessed expression of iodide-handling genes and radioiodide uptake.

Main Results:

  • Inhibitor treatment restored expression of key iodide-handling genes, including sodium/iodide symporter, TSH receptor, and thyroperoxidase.
  • Combinations including SAHA showed synergistic effects.
  • Restored sodium/iodide symporter expression on cell membranes and induced radioiodide uptake, further enhanced by TSH.

Conclusions:

  • Targeting major signaling pathways can restore thyroid gene expression and radioiodide uptake in thyroid cancer.
  • Further research is needed to validate this strategy for effective radioiodine ablation therapy.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...